Previous Page
Sand 9, Inc., a pioneer in precision MEMS timing products for wireless and wired applications, announced that Ericsson (NASDAQ: ERIC), a worldleading provider of telecommunications equipment and services to mobile and fixed network operators, has invested $3 million in the company. Sand 9’s micro-electromechanical systems (MEMS) timing products offer significant advantages over legacy quartz crystal solutions, which currently dominate this market. Sand 9’s timing products offer greater immunity to electromagnetic interference (EMI) and vibration in combination with low noise and high stability, which ensures precision timing – even in ruggedized environments. Founded in 2007 in Cambridge, MA, Sand 9 is a pioneer in advanced MEMS timing technology.
Solarmer Energy, Inc., and Phillips 66 (NYSE: PSX) South China University of Technology (SCUT), and have successfully set a new world record in power conversion efficiency for polymer-based organic photovoltaic (OPV) cells. The 9.31 percent efficiency was certified by the Newport Technology & Application Center’s Photovoltaic Lab in Long Beach, Calif. Solarmer is developing transparent, lightweight, flexible, plastic solar panels, which are expected to cost a fraction of what silicon solar panels cost. These solar panels will create new markets that are currently not addressable with conventional silicon solar panel technology. The company was founded in 2006 to commercialize technology developed at UCLA. It now is based in El Monte, Calif., USA.
http://www.solarmer.com http://www.phillips66.com
Starpharma Holdings Ltd (OTCQX: SPHRY) announced the signing of an agreement with global pharmaceutical company AstraZeneca giving AstraZeneca the right to test certain proprietary Starpharma oncology molecules based on Starpharma’s dendrimer technology. Under the agreement Astra-Zeneca will undertake oncology studies using specific Starpharma Holdings also announced completion of recruitment in its two Phase 3 trials investigating Vi- vaGel® as a treatment for bacterial vaginosis (BV). The Phase 3 treatment trials were conducted across more than 30 international sites, and recruited 250 pati- ents per trial. The results of the trials are expected to be available by early December 2012 – following the completion of patient follow-up, data collection and the necessary statistical analyses. Starpharma also released its Appendix 4C – Quarterly Cashflow report for the period ended September 2012. The cash balance at 30 September 2012 was $37.6 million. Total operating and investing cash outflows for the quarter were $5.9 million; with net proceeds from the issue of shares totaling $0.8 million, resulting in a net decrease in cash of $5.1 million. The cash burn for the quarter is in line with budget.
Stella Specialty Chemicals, a holding of Nanostart Asia Pacific, starts marketing of its products in Asia. The company has set up its manufacturing site in Singapore and all necessary licenses for the production of specialty chemicals have been granted by the authorities. The marketing strategy of the com- pany considers sales via distributors all over Asia as well as direct sales to OEMs in the region. A number of well known electronic component manufacturers have been served with trial shipments as potential Starpharma drug-dendrimer conjugate molecules. The primary objective of the program is to assess the suitability of the dendrimer constructs for particular applications within the cancer field.